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Abstract
Background:  Serratia marcescens is a gram-negative bacterium and often causes nosocomial
infections. There have been few studies of the virulence factors of this bacterium. The only S.
marcescens hemolytic and cytotoxic factor reported, thus far, is the hemolysin ShlA.
Results: An S. marcescens shlAB deletion mutant was constructed and shown to have no contact
hemolytic activity. However, the deletion mutant retained hemolytic activity on human blood agar
plates, indicating the presence of another S. marcescens hemolytic factor. Functional cloning of S.
marcescens identified a phospholipase A (PhlA) with hemolytic activity on human blood agar plates.
A phlAB deletion mutant lost hemolytic activity on human blood agar plates. Purified recombinant
PhlA hydrolyzed several types of phospholipids and exhibited phospholipase A1 (PLA1), but not
phospholipase A2 (PLA2), activity. The cytotoxic and hemolytic activities of PhlA both required
phospholipids as substrates.
Conclusion: We have shown that the S. marcescens phlA gene produces hemolysis on human
blood agar plates. PhlA induces destabilization of target cell membranes in the presence of
phospholipids. Our results indicated that the lysophospholipids produced by PhlA affected cell
membranes resulting in hemolysis and cell death.
Background
Serratia marcescens is widely distributed in natural envi-
ronments and has emerged in the last two decades as an
important nosocomial pathogen, mainly in immunocom-
promised patients [1,2]. Although S. marcescens patho-
genicity is poorly understood, its extracellular secreted
enzymes, including several types of proteases, are candi-
dates for virulence factors [2]. Other factors (e.g., fimbria
for adhesion, lipopolysaccharide (LPS), and ShlA hemo-
lysin) have also been suggested as virulence factors [2,3].
Hemolysins are produced by various pathogenic bacteria
and have been proposed to be responsible for their patho-
genesis [4-6]. These hemolysins, including S. marcescens
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ShlA, also have cytolytic activity [7]. One type of hemo-
lysin/cytolysin is a group of pore-forming toxins. This
type of toxin typically forms a homo-oligomer integrated
into its target cell membrane, thereby changing the cell
permeability and leading to cell death. ShlA has been
shown to increase cell membrane permeability, but not to
form an oligomer [3]. Another type of hemolysin has
phospholipase C (PLC) activity. The α-toxin produced by
Clostridium perfringens is the most thoroughly investigated
PLC, but the molecular mechanism for its disruption of
red blood cells (RBC) is not fully understood [8]. The
pathogenic effects of other types of phospholipases, such
as phospholipase A (PLA), have been studied in various
bacteria, including Helicobacter pylori (PldA) [9], Legionella
pneumophila (PlaA) [10], Campylobacter coli (PldA) [11],
and Yersinia enterocolitica (YplA) [12]. Two extracellular
PLAs, PhlA and PlaA, have been described previously in
Serratia species [13,14]. PlaA is produced in Serratia sp.
strain MK1 isolated from Korean soil [14]. The amino acid
sequence of PlaA was found to have significant similarity
(80%) to PhlA from S. marcescens MG1, which was origi-
nally classified as S. liquefaciens [13-15]. However, the
cytotoxic and hemolytic activities of these enzymes have
remained unclear, and the importance of PLA in bacterial
virulence is not well understood.
S. marcescens produces two types of hemolysins: contact-
dependent hemolysin and extracellular hemolysin [16].
The ShlA hemolysin has cytolytic and contact-dependent
hemolytic activity, but little is known about the S. marces-
cens secreted hemolysin. The gene cassette responsible for
the production and secretion of ShlA is shlAB, with shlA
encoding the structural gene for hemolytic activity and
shlB required for activation and secretion of ShlA in the
presence of the cofactor phosphatidylethanolamine [17].
ShlA production is higher at 30°C than at 37°C [18].
In this study, we cloned an S. marcescens gene that pro-
duced hemolytic activity on human blood agar plates. The
gene, designated phlA, encoded an extracellular PLA activ-
ity. We also showed that PhlA hydrolyzed phospholipid
to lysophospholipid, which directly lysed human, horse,
and sheep RBC and cultured cells.
Methods
Reagents
Taurocholic acid sodium salt hydrate and ethylenedi-
amine-N,N'-diacetic acid (EDDA), L-α-phosphatidylcho-
line (PC) and L-α-phosphatidylethanolamine (PE) were
purchased from Sigma. Cardiolipin (CL), L-3-phosphati-
dylinositol (PI) and sphingomyelin (SPM) and L-α-lyso-
phosphatidylcholine (LPC) were purchased from Doosan
Serdary Research Laboratories. Lecithin from egg yolk was
purchased from Wako Chemicals. Phospholipase A2
derived from bovine pancreas was purchased from Sigma.
Bacterial strains, plasmids, and media
S. marcescens niid 298 strain is one of our reference strains
for serotyping, which is originally isolated from urine. E.
coli K-12 DH5α and pBR322 were used for shotgun clon-
ing. The pGEM-Easy vector (Promega) was used for clon-
ing. pCold1 and pG-KJE8 (TaKaRa) were used as
expression vectors in E. coli BL21 [F-, ompT, hsdSB (rB- mB-
), gal, dcm] (TaKaRa). Unless otherwise specified, bacteria
were grown in Luria broth (LB). Antibiotics were added as
required for the following final concentrations: ampicil-
lin, 200 μg/ml; kanamycin, 100 μg/ml; and chloramphen-
icol, 20 μg/ml.
Peripheral human blood was obtained from healthy vol-
unteers with their informed consent according to the
guidelines laid down by the Ethics Committee of National
Institute of Infectious Diseases. Horse and sheep blood
were obtained from Kohjinbio. RBC were washed three
times with phosphate-buffered saline (PBS) by centrifuga-
tion at 850 × g for 10 min. Washed RBC were resuspended
in PBS to a final concentration of 2.5% (vol/vol) and used
for hemolytic activity assays. Blood agar plates contained
12.5 g Bacto-tryptone, 5 g NaCl, 5% (v/v) RBC, 10 mM
CaCl2, and 15 g agar (per liter), and the pH was adjusted
to 7.2 [19]. PCY medium plates, which contained 10 g
Bacto-tryptone, 5 g yeast extract, 5 g NaCl, 20 mM CaCl2,
5 g taurocholic acid, 15 g egg yolk lecithin, and 15 g agar
(per liter), were used for determining phospholipase
activity [14].
Functional cloning
Shotgun cloning was used to identify hemolytic factors as
follows. S. marcescens strain niid 298 genomic DNA was
digested with Sau3AI, ligated into a pBR322 vector BamHI
site, and introduced into E. coli DH5α. Colonies that
induced hemolysis on human blood agar were selected as
candidate hemolysin clones. The inserted fragments were
amplified by PCR and complete fragment sequences were
determined using a 3130 Genetic Analyzer (Applied Bio-
systems). The S. marcescens nucleotide sequences deter-
mined in this work have been deposited in the DDBJ/
EMBL/GenBank databases under the following accession
numbers: AB505202 and AB505203 for the phlA and phlB
genes of S. marcescens niid 298.
Construction of mutant strains
A one-step inactivation method [19-21] was used to
obtain shlBA and phlAB deletion mutants. For construc-
tion of a shlBA  deletion mutant, PCR products were
amplified from pKD4 [19] with primers ShlBA5' (5'-
GGTTAACCTCATGGATTGGGCTGGCTGCCCCGGCG-
GCCTCTCATAGTGTAGGCTGGAGCTGCTTC-3') and
ShlBA3' (5'-GCAAAACTCCACGCCTGCCGTCATGCTTCA
TGTCACTGTCAGCAACATATGAATATCCTCCTTAGT-3'),
which flank the 5' and 3' termini of the shlBA gene with 45BMC Microbiology 2009, 9:261 http://www.biomedcentral.com/1471-2180/9/261
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bp homology, and electroporated into S. marcescens niid
298 carrying pKD46 [20]. For construction of a phlAB
deletion mutant, primers PhlAB5' (5'-
AGCGCCAGTAAGGCTATCGCCAGCGCCCGCCGCAAG
CGACCCCCTCATATGAATATCCTCCTTAGT-3') and
PhlAB3' (5'-TGCCTAAGAAAAAACCGCCTGTACAGGCG-
GTT TTTTTATGGGCGTCATATGAATATCCTCCTTAGT-3')
were used. The correct mutation was verified by PCR using
three different primer sets as described previously [20].
Preparation of purified PhlA
The full-length phlA gene was obtained from S. marcescens
niid 298 genomic DNA by PCR with primers phlA5' (5'-
GAATTCCATATGAGTATGCCTTTAAGTTTTACCTCTG-3')
and phlA3' (5'-GCTATCTAGATCAGGCATTGGCCT-
TCGCCTC-3'). The 5'- and 3'-termini of the PCR product
were NdeI and XbaI restriction enzyme sites, respectively.
The PCR fragment cleaved by these restriction enzymes
was inserted into NdeI/XbaI-digested pCold1, which has a
histidine tag site at the 5'-terminus, and used to transform
E. coli DH5α. The resulting plasmid, pCold1-phlA, was
introduced into E. coli BL21 harboring pG-KJE8 [22]. The
transformant was used for expression of His-PhlA accord-
ing to the manufacturer's instructions.
To purify the His-PhlA recombinant protein, cells were
harvested, lysed by lysis buffer [50 mM NaH2PO4, 300
mM NaCl, 10 mM imidazole, and protease inhibitors
(one tablet of inhibitor mixture (Complete, Roche)/25
ml)], incubated in a final concentration of 1 mg lys-
ozyme/ml for 20 min on ice, and then disrupted by soni-
cation. Cell debris was removed by centrifugation. The
supernatant was analyzed by affinity chromatography
using Ni-NTA agarose (Qiagen) under native conditions
without a protease inhibitor. After dialysis against PBS,
the purified protein was concentrated by Amicon Ultra-15
(MWCO = 30 K; Millipore). The protein concentration
was determined using a BCA Protein Assay Kit (Pierce).
We obtained approximately 1.9 mg purified recombinant
protein (His-PhlA) from one liter of culture. The purified
protein was analyzed by sodium dodecyl sulfate-polyacr-
ylamide gel electrophoresis (SDS-PAGE) with Coomassie
blue staining.
Determination of hemolytic activity
The assay for contact-dependent hemolysis was per-
formed as described previously [23]. Briefly, S. marcescens
cells were cultured in LB containing EDDA (2 mM) at
30°C or 37°C and harvested at log phase. Bacteria (1.2 ×
108 cells in 50 μl PBS) were mixed with 70 μl RBC and
centrifuged (500 × g for 1 min). The mixture was incu-
bated for 60 min at 30°C or 37°C with shaking. Hemo-
globin released from lysed RBC was measured
spectrophotometrically at 405 nm. Osmotic lysis of RBC
in distilled water was taken as 100% hemolysis.
The hemolytic activity of purified PhlA in solution was
measured as described previously [24,25], with the fol-
lowing modification. The RBC suspension containing
0.15 mg lecithin/ml, 0.06% taurocholic acid and 2 mM
CaCl2 was incubated with His-PhlA at 37°C for 1 h. After
centrifugation (500 × g for 10 min) the supernatant was
assayed spectrophotometrically. RBC were not lysed by
this low concentration of taurocholic acid.
Detection of phospholipase A activity
Fluorogenic, BODIPY FL-labeled, phospholipase A sub-
strates bis-BODIPY FL C11-PC, PED6, and PED-A1 (Invit-
rogen) were used to determine the specificities of PLA1
and PLA2. The bis-BODIPY FL C11-PC is glycerophospho-
choline with BODIPY FL dye-labeled sn-1 and sn-2 acyl
chains. PED-A1 and PED6 are glycerophosphoeth-
anolamine with dye-labeled sn-1 and sn-2 acyl chains,
respectively. The bis-BODIPY FL C11-PC was self-
quenched, and PED-A1 and PED6 fluorescence was
quenched by added dinitrophenol. Release of the fluoro-
phores by acyl chain cleavage by either PLA1 or PLA2
results in increased fluorescence. Each substrate solution
(45 nM) was prepared in 10 mM Tris-HCl (pH 8.0), 100
mM NaCl, and 10 mM CaCl2 [26]. A 90 μl sample of each
substrate solution was incubated with various concentra-
tions of enzymes (10 μl) in 96-well plates for 6 min, and
fluorescence intensity was measured. The fluorescence
background for each quenched substrate solution was
determined without PhlA treatment. Fluorescence inten-
sity was measured at 485 nm excitation and 530 nm emis-
sion using an Appliskan fluorescence microplate reader
(Thermo Electron Corporation).
Assay for free fatty acids from phospholipids
Non-esterified fatty acids (NEFA) released from phos-
pholipids (PLs) were quantitated by an enzymatic colori-
metric method using a NEFA-C kit (Wako chemical,
Japan) [27]. Substrate solutions were prepared by dissolv-
ing 5 mg of various phospholipids in 1 ml of a solution of
2% taurocholic acid and 10 mM CaCl2. A 29 μl sample of
each substrate solution was mixed with 1 μl His-PhlA and
incubated at 37°C for 1 h. Background NEFA absorbance
was estimated using non-His-PhlA treated substrates.
NEFA concentrations were calculated from a calibration
curve determined using oleic acid as a standard.
Thin-layer chromatography
PC (0.65 mM) was incubated with 8.3 μM His-PhlA at
37°C for 1 h in the presence of 2% taurocholic acid and
10 mM CaCl2. The reaction was terminated by placing the
samples on ice. The samples were dried with a SpeedVac
concentrator, dissolved in 20 μl chloroform/methanol (2/
1, vol/vol), applied to thin-layer chromatography plates
(PE SILG; Whatman), and separated with chloroform/
methanol/water (65/25/4, vol/vol/vol). LPC (1.0 mM)BMC Microbiology 2009, 9:261 http://www.biomedcentral.com/1471-2180/9/261
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was analyzed on the same plate as a reference. Phosphol-
ipids on the plate were visualized with Dittmer-Lester rea-
gent [28].
Cell culture and cytolysis
HeLa and 5637 cells (derived from a human cervical can-
cer and bladder carcinoma, respectively) were grown in
Dulbecco's Modified Eagle's Medium (DMEM) and 1640
RPMI medium, respectively, plus fetal calf serum (10% v/
v) at 37°C in the presence of 5% CO2. At 24 h before the
start of cytolysis experiments, 96-well culture plates were
seeded with 1.0 × 104 cells per well. After washing with
medium, the cells were incubated with various concentra-
tions of His-PhlA in 100 μl lecithin solution (313 μg/ml
lecithin, 0.125% taurocholic acid, and 2 mM CaCl2 in
DMEM) at 37°C for 1 h. Cytolysis was measured as the
amount of lactate dehydrogenase (LDH) released as deter-
mined with a CytoTox 96 Non-Radioactive Cytotoxicity
Assay Kit (Promega) [29]. Complete (100%) cytolysis was
determined by measuring LDH release after cell lysis with
1% Triton X-100.
Results
Identification of an S. marcescens hemolysin other than 
ShlA
S. marcescens niid 298 showed hemolytic activity visible as
clear zones on human, sheep, and horse blood agar plates
(Fig. 1A). The zones were larger for bacteria grown at
30°C than at 37°C. S. marcescens also showed contact-
dependent hemolytic activity on human RBC, which was
also greater for bacteria grown at 30°C than at 37°C (Fig.
1B).
Since ShlA is the only hemolysin that has been reported in
S. marcescens [7], we constructed an shlBA  deletion
mutant. The mutant grown at both 30°C and 37°C lost its
contact-dependent hemolytic activity (Fig. 1B), but
retained hemolytic activity on human blood agar plates
(Fig. 1C). These results indicated that S. marcescens had a
hemolysin other than ShlA.
Functional cloning of a novel hemolysin
To clone the S. marcescens hemolysin identified on human
blood agar, we constructed a library of S. marcescens strain
niid 298 DNA in E. coli DH5α. Approximately 13,000
transformants were examined for hemolytic activity on
human blood agar plates and four hemolysin-positive
clones were obtained. One clone showed hemolytic activ-
ity on human, sheep, and horse blood agar plates, but the
other three clones showed activity only on human blood
agar.
Sequence analysis of the inserts in the three clones with
hemolytic activity only on human blood agar showed that
all three had phlA and phlB genes with nucleotide similar-
ity to phlA and phlB (94% and 94%, respectively) of S.
marcescens MG1, which was originally classified as S. liq-
uefaciens [13,15]. The phlA and phlB deduced amino acid
sequences were similar to Serratia sp. MK1 PlaA and PlaB
(81% and 73% identity) and Y. enterocolitica YplA and
YplB (60% and 50% identity) [12,14]. PhlB has been sug-
Hemolytic activity of S. marcescens Figure 1
Hemolytic activity of S. marcescens. (A) Hemolytic activ-
ity of S. marcescens strain niid 298 on several blood agars. 
Cells (1 × 106) were cultured overnight, and then inoculated 
on various blood agars and incubated at 30°C or 37°C for 16 
h. Clear zones indicated hemolysis. (B) Contact hemolysis 
assay for human RBC. Cells harvested in log phase were 
mixed with washed human RBC and incubated at 30°C or 
37°C for 1 h with shaking. Released hemoglobin was meas-
ured spectrophotometrically as absorbance at 405 nm. 
Results are shown as percent lysis compared to complete 
lysis of RBC in distilled water. (C) Hemolytic activity of the 
shlBA deletion mutant on human blood agar. Experiments 
were performed as in (A).BMC Microbiology 2009, 9:261 http://www.biomedcentral.com/1471-2180/9/261
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gested to be an inhibitor of PhlA inside the cell in which
they are produced, thereby functioning to prevent PhlA
activity until its release into the extracellular milieu [30].
Although there are no data about a PhlA hemolytic activ-
ity, since some other phospholipases have hemolytic
activity, we investigated whether the S. marcescens phlA
gene product might be a hemolysin.
Hemolytic activity of S. marcescens PhlAB is on human 
blood agar
To confirm that phlAB had phospholipase and hemolytic
activities, we constructed the phlAB  expression vector
pGEMeasy-phlAB and introduced it into E. coli DH5α. E.
coli DH5α/pGEMeasy-phlAB showed a clear zone on PCY
agar plates containing egg yolk lecithin as a substrate for
phospholipase, in contrast to E. coli DH5α carrying an
empty vector, indicating that PhlAB produced in E. coli
DH5α/pGEMeasy-phlAB  degraded phospholipids (Fig.
2A). In addition to phospholipase activity, E. coli DH5α/
pGEMeasy-phlAB  showed hemolytic activity on human
blood agar plates (Fig. 2A).
We next constructed an S. marcescens niid 298 phlAB dele-
tion mutant. The S. marcescens ΔphlAB mutant did not
exhibit hemolytic activity on human blood agar plates or
phospholipase activity on PCY agar plates (Fig. 2A). In
contrast, the ΔphlAB mutant retained contact-dependent
hemolytic activity against human RBC (data not shown).
An S. marcescens ΔphlAB mutant carrying phlAB regained
hemolytic and phospholipase activities (Fig. 2A), con-
firming that PhlAB had both activities.
Characterization of recombinant His-PhlA protein
To investigate PhlA hemolytic and phospholipase activi-
ties, we purified a recombinant His-PhlA protein pro-
duced in E. coli (Fig. 2B). Purified His-PhlA had hemolytic
activity human blood agar plates, but not on horse or
sheep blood agar plates, and phospholipase activity on
PCY agar plates (data not shown). These data indicated
that PhlA had hemolytic and phospholipase activities,
indicating that PhlB was not required for the PhlA activi-
ties.
We next studied the specificity of PhlA phospholipase.
Phospholipase A (PLA) hydrolyzes the fatty acids of PLs at
position sn-1 for phospholipase A1 (PLA1) and sn-2 for
phospholipase A2 (PLA2), resulting in the release of free
fatty acids and production of lysophospholipid (LPL). We
measured free fatty acids after incubation of PhlA with
various PLs [phosphatidylcholine (PC), cardiolipin (CL),
L-3-phosphatidylinositol (PI), L-α-phosphatidyleth-
anolamine (PE), and sphingomyelin (SPM)]. These exper-
iments showed that PhlA cleaved ester bonds within PC,
CL, PI, and PE and released fatty acids in a concentration-
dependent manner, but did not hydrolyze SPM in our
experimental conditions (Fig. 2C).
Previous reports have shown that some bacterial PLA2
enzymes have hemolytic activity [5,6,31]. However, there
is little information on hemolysis caused by bacterial
PLA1 enzymes. To confirm that S. marcescens PhlA had
PLA1 activity, we tried to identify the site that is hydro-
lyzed by PhlA using fluorescent PLs as substrates [31,32].
As shown in Figure 3A, S. marcescens PhlA and bovine
pancreatic PLA2 released fluorescent fatty acids from bis-
BODIPY FLC11-PC, indicating that PhlA had phospholi-
pase A activity (Fig. 3A). PhlA released fluorescent fatty
Phospholipase and hemolytic activities of S. marcescens PhlA Figure 2
Phospholipase and hemolytic activities of S. marces-
cens PhlA. (A) Overnight cultures of wild-type strain S. 
marcescens niid 298, E. coli DH5αcells carrying pGEMeasy, E. 
coli DH5αcarrying pGEMeasy-phlAB, S. marcescens niid 298 
phlAB deletion mutant, and S. marcescens niid 298 phlAB dele-
tion mutant carrying pGEMeasy-phlAB (1 × 106 cells) were 
inoculated on blood agar plates and PCY agar plates and 
incubated at 37°C for 16 and 24 h, respectively. (B) Purified 
His-PhlA (1 μg) was separated by 12.5% SDS-PAGE, and then 
was stained with Coomassie blue. Protein standards were in 
lane M, with relative molecular masses (kDa) at the left. (C) 
Various phospholipids were mixed with His-PhlA and incu-
bated at 37°C for 1 h. Free fatty acids (FFA) released from 
phospholipids were detected using a NEFA-C kit. The 
amount of FFA was determined from an oleic acid calibration 
curve. Values are averages ± SE of three independent experi-
ments.BMC Microbiology 2009, 9:261 http://www.biomedcentral.com/1471-2180/9/261
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acids from PED-A1 in a concentration-dependent manner
whereas control PLA2 did not produce fluorescence (Fig.
3B), indicating that PhlA was able to cleave ester bonds at
PL sn-1 sites. Using PED-6 as substrate, although fluores-
cence intensity increased after PhlA treatment, the maxi-
mum fluorescence was 6-fold lower than after PLA2
treatment (Fig. 3C). These results are in agreement with
the proposal that His-PhlA has PLA1, but not PLA2, activ-
ity.
PhlA requires phospholipids to express hemolytic activity
The studies described above showed that PhlA had hemo-
lytic and phospholipase A1 activities. To investigate PhlA
activity on a range of target cells, we studied the activity of
purified PhlA in a solution reaction system with different
types of cells. Interestingly, in contrast to the results on
blood agar plates, PhlA hemolytic activity on human RBC
was not detected in solution reactions, even at a PhlA con-
centration as high as 18 mM (Fig. 4A). This result indi-
cated that PhlA did not act directly as a hemolysin on
RBC. It has been reported that several animal venoms con-
taining PLA exhibit an indirect hemolytic activity in the
presence of lecithin [23,24]. When egg yolk lecithin or PC
was added to the PhlA solution reaction system, PhlA was
observed to have indirect hemolytic activity on human
RBC (Fig. 4A).
Lysophospholipid (LPL) is one of the products from PLs
hydrolyzed by PLA1. Therefore, we investigated whether
LPL could cause hemolysis of human RBC. Lysophos-
phatidylcholine (LPC) was found to have hemolytic activ-
ity on human RBC in the solution reaction system (Fig.
4B). Using thin-layer chromatography, LPC was found to
be produced by incubation of PC with PhlA (Fig. 4C).
To determine the range of cells affected by PhlA, we exam-
ined various kinds of RBCs. As described above, PhlA
lysed human RBC, but not horse or sheep RBC, on blood
agar plates. However, all three types of RBC were lysed by
PhlA in a lecithin-dependent manner in the solution reac-
tion system (Fig. 4D). An explanation of these results may
be that, in human blood agar plates, enough PL might be
released from collapsed RBC during agar plate prepara-
tion to allow PhlA to produce LPL. When PL was added to
sheep and horse blood agar plates, we clearly detected
PhlA-dependent hemolytic activity on horse and sheep
blood agar plates (data not shown).
Since PC required 6-fold more PhlA than lecithin for
induction of 50% hemolysis (Fig. 4A), the egg yolk leci-
thin used in this study might have contained enough LPL
for hemolysis. However, no hemolysis was induced by
lecithin without PhlA treatment (Fig. 4D).
Taken together, these results indicated that PhlA phos-
pholipase activity hydrolyzed PL and produced LPL. Since
LPL is known to be a surfactant [33], it may have been the
final effector leading to destabilization of the RBC mem-
brane and hemolysis.
Cytotoxicity of PhlA in the presence of phospholipid
We examined the cytotoxicity of PhlA using HeLa and
5637 cells. PhlA had cytotoxic activity against both HeLa
and 5637 cells in the presence of lecithin (Fig. 4E). To
investigate the cytolytic activity of late log phase S. marc-
escens  culture supernatants, S. marcescens was grown at
37°C for 6 h in LB containing PL. Up to 48-fold dilutions
of the S. marcescens culture supernatant induced cell death
of both HeLa and 5637 cells, while supernatant of S. marc-
escens ΔphlAB cultured under the same conditions had no
effect on HeLa or 5637 cells, indicating that PhlA was an
extracellular secretion product (data not shown).
Discussion
A wide range of pathogenic bacteria produce phospholi-
pases, and the putative role of PLA in virulence has been
studied in some of these pathogens. Outer membrane-
associated PLAs (OMPLAs) were first identified in E. coli
[34] and orthologs were subsequently reported in numer-
ous gram-negative bacteria, including H. pylori (PldA) [9].
The OMPLAs have been well-characterized and are
thought to enhance bacterial growth, colonization, and
survival. In addition to modulation of the bacterial mem-
brane, some OMPLAs were shown to have contact-
dependent hemolytic/cytolytic activities [35]. Another
group of PLAs (e.g., YplA [12], ExoU [36], PlaA [10], and
SlaA [37]) is secreted from bacterial cells. Purified ExoU
and SlaA [38,39] recombinant proteins do not show cyto-
toxic activity when added exogenously, and there is little
information on the cytotoxicity of other secretory PLAs.
To our knowledge, ShlA is the only previously reported
hemolysin from S. marcescens. Although, a ΔshlAB mutant
showed hemolytic activity on blood agar plates, it did not
exhibit contact-dependent hemolytic activity (Fig. 1C).
Therefore, we performed functional cloning, which iden-
tified PhlA as an S. marcescens candidate hemolytic factor
(Fig. 2A).
In the experiments reported here, we described the hemo-
lytic and cytotoxic activities of S. marcescens PhlA. PhlA
itself did not directly induce the destabilization of target
cell membranes, but the LPL produced from PL by PhlA
phospholipase activity showed hemolytic and cytolytic
activities. Therefore, PhlA and ShlA have different hemo-
lytic mechanisms. In addition, ShlA was expressed at
lower temperature, but its expression decreased at 37°C
[17]. In contrast, PhlA was expressed at 37°C, although its
temperature regulation has not been elaborated. Also,
PhlA hydrolyzed phosphoethanolamine (Fig. 3C), which
is required for ShlA activity [16], implying that PhlA pro-
duction could potentially regulate ShlA activity.BMC Microbiology 2009, 9:261 http://www.biomedcentral.com/1471-2180/9/261
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PLA1 and PLA2 activities of PhlA. PhlA activity was evaluated in a fluorescence enhancement assay using the following PLA flu- orescence substrates: (A) bis-BODIPYFLC11-PC, (B) PED-A1, and (C) PED6 Figure 3
PLA1 and PLA2 activities of PhlA. PhlA activity was evaluated in a fluorescence enhancement assay using the 
following PLA fluorescence substrates: (A) bis-BODIPYFLC11-PC, (B) PED-A1, and (C) PED6. Fluorescence 
intensity was measured at 485 nm excitation and 530 nm emission using a fluorescence microplate reader (Appliskan; Thermo 
Electron Corporation). Open circles show His-PhlA; filled circles show PLA2 from bovine pancreas as a control. Values are 
averages ± SE from three independent experiments.
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Phospholipid requirements of PhlA hemolytic and cytotoxic activities Figure 4
Phospholipid requirements of PhlA hemolytic and cytotoxic activities. (A) Human RBC were mixed with various 
concentrations of His-PhlA in the absence (open circles) or presence of lecithin (filled circles) or phosphatidylcholine (filled 
squares) and incubated at 37°C for 1 h. (B) Human RBC were mixed with various concentrations of lysophosphatidylcholine 
(LPC) and incubated at 37°C for 1 h. (C) Products of the reaction of PC with (+) or without (-) His-PhlA were analyzed by 
thin-layer chromatography. (D) Human (circles), sheep (triangles), and horse (squares) RBC were mixed with 8.3 μM PhlA 
(filled symbols) or no PhlA (open symbols) and incubated at 37°C for 1 h in the presence of various concentrations of lecithin 
with 2 mM CaCl2. (E) HeLa and 5637 cells were exposed to various concentrations of His-PhlA for 1 h in the presence of leci-
thin. His-PhlA cytotoxicity was evaluated with a CytoTox 96 Non-Radioactive Cytotoxicity Assay kit (Promega). Open and 
filled circles show HeLa and 5637 cells, respectively. Values are averages ± SE from three independent experiments. (A), (B), 
and (D) Results are expressed as percent lysis compared with lysis of RBC in distilled water, as in the contact hemolysis assay 
(Fig. 1).
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Tsubokura et al. [40] reported PL-dependent hemolytic
activity in a Y. enterocolitica culture filtrate. Schmiel et al.
[12] independently identified this hemolysin as a lecithin-
dependent phospholipase A (YplA). However, there were
no data on whether YplA also had cytotoxic activity in the
presence of PL, similar to that reported here for S. marces-
cens PhlA.
PhlA cleaved the ester bond of PL at the sn-1 site, and pro-
duced fatty acids and LPL from several PLs; e.g., PC, PS,
PE, and CL (Fig. 2C). LPL production by PL cleavage
might explain why PL addition was required for PhlA
hemolytic activity of (Fig. 4A), since LPL may act as a sur-
factant and induce hemolysis. We detected PhlA hemo-
lytic activity on human blood agar, but not on sheep or
horse blood agar (Fig. 1A). However, sheep and horse
RBC were lysed with purified PhlA in the presence of PL.
This difference may be explained if PLs are released from
human RBCs during the preparation of blood agar, and
then become substrates for added or secreted PhlA result-
ing in the production of LPL. In agreement with this pos-
sibility, we observed hemolysis around bacterial colonies
by addition of egg yolk lecithin to sheep and horse blood
agar plates (date not shown).
Our results on the mechanism of PhlA cytotoxic activity
allowed us to quantitate cytotoxic activity in a liquid
assay. Numerous reports have shown that bacterial phos-
pholipases contribute to pathogenesis by directly hydro-
lyzing host membrane phospholipids and modulation of
the host immune system via the production of lipid sec-
ond messengers (5, 6, 31). Although PhlA did not pro-
duce direct cytotoxicity on cultured cells, the pathogenetic
role of indirect cytotoxicity via LPL production should be
investigated.
It has been reported that Pseudomonas aeruginosa ExoU
inhibited neutrophil function in the lungs of infected
mice [41] and group A Streptococcus (GAS) SlaA contrib-
uted to colonization of the upper respiratory tract [37].
Furthermore, a PhlA-like phospholipase, Y. enterocolitica
YplA, has been shown to play a role in bacterial coloniza-
tion of the intestinal tract and increasing the pathological
changes resulting from the host inflammatory response in
the mouse model [12]. The high degree of homology
between YplA and PhlA suggests that PhlA may also play
a role in S. marcescens colonization, since S. marcescens is
thought to be a commensal in the intestinal tract where
PLs are supplied by the host diet. The pathogenic role of
PhlA remains to be elaborated.
Conclusions
In this report, we have identified a hemolytic and cyto-
toxic factor in S. marcescens other than the previously
reported ShlA. This new factor, PhlA, had phospholipase
A1 activity. It is interesting to note that the hemolytic and
cytotoxic activity of PhlA depend on the presence of phos-
pholipids in addition to those in target cell membranes
and seems to be mediated by the LPL product of the PhlA
enzyme. Our results contribute to understanding the
pathogenic role of microbial PLA.
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